Una farmacéutica de Mataró logra que la UE apruebe una terapia única contra una enfermedad infantil mortal
The pharmaceutical company Minoryx from Mataró, Spain, has developed and received EU approval for a unique therapy targeting a fatal childhood disease, adrenoleukodystrophy. The drug development was rooted in research begun two decades ago at a public hospital.
pharmaceutical EU approval adrenoleukodystrophy childhood disease Minoryx